Trombola 50 mg: Innovating Hematologic Care with Precision Treatment

Eltrombopag Export: Bangladeshi ITP Brands for KSA

Last Updated: August 2026

Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.

Medical Review: Reviewed by Dr. Rakib Uddin Ahmed, MBBS, MD (Hematology)

Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from SFDA and DGDA (Directorate General of Drug Administration, Bangladesh).

Sources: elbonix.com.bd, global.beaconpharma.com.bd, dailymed.nlm.nih.gov, drugs.com, drugs.com, drugs.com, drugs.com

Eltrombopag — Trombola, Treptora, Elopag, Elbonix
Eltrombopag — Trombola, Treptora, Elopag, Elbonix

Key Takeaways

  • Eltrombopag is a thrombopoietin receptor agonist that helps stimulate platelet production in chronic immune (idiopathic) thrombocytopenia (ITP).
  • It is approved for chronic ITP in patients aged 1 year and older who have had an insufficient response to prior treatments such as corticosteroids, immunoglobulins, or splenectomy.
  • Eltrombopag is available in tablet and oral suspension forms, offering flexibility for both adult and pediatric patients.
  • Common side effects include nausea, diarrhea, vomiting, thrombocytopenia, and anemia, while serious risks include hepatotoxicity, thrombotic events, and bleeding requiring ongoing monitoring.
  • Trombola, Treptora, Elopag, and Elbonix are the Bangladeshi-manufactured eltrombopag brands available for export to Saudi Arabia.
  • Exports are supplied in line with SFDA import and registration requirements to support pharmacies, hospitals, and distributors in Saudi Arabia.

Product Overview: Eltrombopag for Chronic ITP

Eltrombopag is a small-molecule thrombopoietin receptor agonist that stimulates platelet production, addressing the underlying mechanism of low platelet counts in chronic immune (idiopathic) thrombocytopenia (ITP). As a member of the thrombopoietin receptor agonist (hematopoietic agent) class, eltrombopag therapy offers a targeted, non-immunosuppressive approach for patients requiring sustained platelet support.

Eltrombopag is available in multiple oral dosage forms to accommodate different patient populations, including tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths, as well as oral suspension formulations in 12.5 mg and 25 mg strengths. This range of forms allows flexibility for adult and pediatric patients who may require lower or titratable doses, or who have difficulty swallowing tablets.

This article focuses on the Bangladeshi-manufactured brands available for export — Trombola, Treptora, Elopag, and Elbonix — which are formulated using the same active molecule and are intended for procurement by pharmacies, hospitals, and distributors in Saudi Arabia. Specific dosing — including starting dose, titration, and maximum dose — must always be determined by the treating physician in accordance with the official prescribing information for the selected brand and formulation. This overview is intended to support procurement and clinical familiarity, not to replace prescribing guidance.

This content has been prepared with reference to publicly available prescribing information and regulatory documentation for eltrombopag-containing products, and is reviewed periodically to reflect current pharmacological understanding of this therapeutic class.

Eltrombopag — Approved Indications and Clinical Use
Eltrombopag — Approved Indications and Clinical Use

Approved Indications and Clinical Use

Eltrombopag carries three approved indications. Its primary and most widely recognized use is for chronic immune (idiopathic) thrombocytopenia (ITP), approved for patients aged 1 year and older who have had an insufficient response to other treatments such as corticosteroids, immunoglobulins, or splenectomy.

Beyond ITP, eltrombopag is approved for thrombocytopenia associated with chronic hepatitis C, where it is used to allow initiation and maintenance of interferon-based antiviral therapy in patients 18 years and older. It is also approved, in combination with standard immunosuppressive therapy, for severe aplastic anemia in newly diagnosed patients aged 2 years and older. Each indication carries its own age threshold, and these should not be interchanged across clinical contexts.

Across all three indications, eltrombopag therapy is used under close physician supervision, with treatment decisions guided by platelet response, underlying disease status, and hepatic function. For procurement teams and healthcare providers, understanding this indication breadth is useful context, though chronic ITP remains the central focus for most regional demand in Saudi Arabia.

These indication summaries reflect information consistent with internationally recognized prescribing references. They are provided for procurement and educational context; treating physicians should always consult the current, brand-specific prescribing information before making clinical decisions.

Safety Profile: Side Effects and Monitoring

Commonly reported side effects associated with eltrombopag include nausea, diarrhea, vomiting, headache, fatigue, upper respiratory tract infection, rash, myalgia, pharyngitis, back pain, abdominal pain, and peripheral edema. These are generally manageable but should be monitored throughout therapy.

More serious risks warrant closer clinical attention. Eltrombopag carries a risk of hepatotoxicity and hepatic decompensation, requiring regular monitoring of liver function throughout treatment — this risk may be further elevated when eltrombopag is combined with interferon and ribavirin in chronic hepatitis C patients. Additional serious risks include thrombotic and thromboembolic events, increased risk of hematologic malignancies, bone marrow reticulin fiber deposition and fibrosis, cataracts, and the potential for worsening thrombocytopenia or loss of response following discontinuation.

Eltrombopag is metabolized via CYP1A2 and CYP2C8 pathways, which is relevant when evaluating concomitant medications and potential drug interactions. Prescribers should also consider lactation guidance, weighing the developmental and health benefits of breastfeeding against the mother’s clinical need for therapy and any potential risk to the infant. Ongoing hepatic and hematologic monitoring remains central to safe eltrombopag therapy across all approved indications.

This safety overview is intended as general clinical background for healthcare professionals and procurement partners. It does not replace the full prescribing information, and any patient-specific safety concerns should be directed to a qualified physician or pharmacist.

Eltrombopag — Available Brands: Trombola, Treptora, Elopag, Elbonix
Eltrombopag — Available Brands: Trombola, Treptora, Elopag, Elbonix

Available Brands: Trombola, Treptora, Elopag, Elbonix

As a Bangladeshi pharmaceutical supplier, we source and export four eltrombopag brands, each manufactured in Bangladesh to serve regional and international demand, including Saudi Arabia.

Trombola is manufactured by Ziska Pharmaceuticals Ltd., offering eltrombopag in oral tablet form for patients requiring thrombopoietin receptor agonist therapy. Treptora is produced by Genvio Pharma Limited, providing another reliable option within the same therapeutic class. Elopag is manufactured by Everest Pharmaceuticals Ltd., rounding out the tablet-based offerings available for export.

Elbonix, manufactured by Beacon Pharmaceuticals Ltd., is marketed in 25 mg and 50 mg strengths, aligning with the standard tablet strengths used in eltrombopag therapy globally. All four brands are formulated using the eltrombopag active molecule and are produced under Bangladeshi manufacturing standards.

These brands collectively give procurement partners in Saudi Arabia access to a consistent, Bangladeshi-sourced supply chain for eltrombopag, without reliance on Indian-manufactured alternatives. Buyers seeking a specific strength or packaging configuration are encouraged to inquire directly, as availability may vary by brand and production cycle.

Manufacturer details provided here are based on information disclosed by the respective Bangladeshi manufacturers and are intended to support procurement transparency. Buyers should independently verify current manufacturing status and batch documentation as part of standard due diligence.

Eltrombopag — Regulatory Status and Export Compliance for Saudi Arabia
Eltrombopag — Regulatory Status and Export Compliance for Saudi Arabia

Regulatory Status and Export Compliance for Saudi Arabia

All eltrombopag brands referenced in this article — Trombola, Treptora, Elopag, and Elbonix — are manufactured in Bangladesh and exported to Saudi Arabia to meet regional pharmaceutical demand. Our role as a supplier is to facilitate this export pathway, not to manufacture locally within the Kingdom.

Exports to Saudi Arabia are conducted in accordance with the import and registration requirements set by the Saudi Food and Drug Authority (SFDA, sfda.gov.sa). Pharmacies, hospitals, and distributors sourcing eltrombopag through us can expect documentation and support aligned with these regulatory expectations for cross-border pharmaceutical trade.

On a broader level, eltrombopag as a molecule holds long-standing global regulatory recognition, having first received FDA approval in 2008. This reflects the molecule’s established clinical profile internationally, though it should not be interpreted as a brand-specific certification claim for Trombola, Treptora, Elopag, or Elbonix individually. Buyers are encouraged to request current regulatory and compliance documentation for the specific brand and shipment in question.

Regulatory requirements are subject to change, and it remains the responsibility of the importing pharmacy, hospital, or distributor to confirm current SFDA registration status for any specific brand prior to finalizing procurement.

Global Context: Eltrombopag Around the World

Eltrombopag is recognized globally as an established thrombopoietin receptor agonist, with the originator brand Promacta having played a significant role in shaping international awareness of eltrombopag therapy since its initial approval. While originator and other international formulations exist in various markets, our supply focus remains firmly on Bangladeshi-manufactured brands. This ensures a consistent, cost-competitive, and regionally appropriate sourcing pathway for partners across Saudi Arabia, without dependence on originator or Indian-manufactured products.

Eltrombopag — Packaging and Supply Information
Eltrombopag — Packaging and Supply Information

Packaging and Supply Information

Eltrombopag brands available for export are supplied in oral tablet and oral suspension formats, covering strengths from 12.5 mg through 75 mg depending on the brand and formulation. This range supports varied procurement needs, from hospital pharmacy stocking to distributor-level bulk orders.

Packaging configurations are designed to support safe international transport and shelf storage, consistent with standard pharmaceutical export practice. Specific pack sizes, carton quantities, and strength availability can vary by brand and production batch.

For detailed information on current stock, available strengths, and packaging formats for Trombola, Treptora, Elopag, or Elbonix, contact our team directly. We do not publish pricing publicly; all pricing and availability details are provided upon direct inquiry to ensure accuracy for each order.

Why Partner With Us for Eltrombopag Export

We are a Bangladeshi B2B pharmaceutical supplier with established experience exporting essential medicines, including eltrombopag brands, to Saudi Arabia. Our focus is exclusively on Bangladeshi-manufactured products, giving partners a transparent and consistent sourcing relationship built on regulatory awareness and export reliability.

Through our supply network, healthcare providers, pharmacies, and distributors in Saudi Arabia can access Trombola, Treptora, Elopag, and Elbonix — covering multiple tablet strengths to support chronic ITP and other approved eltrombopag indications. We prioritize compliance with SFDA import expectations and work to ensure documentation and logistics align with regional regulatory standards.

If your organization is evaluating suppliers for eltrombopag or related hematologic agents, we invite you to inquire now for current availability, brand options, and pricing details. Our team is ready to support your procurement timelines with dependable, Bangladeshi-sourced supply.

Frequently Asked Questions

What is eltrombopag used for?

Eltrombopag is primarily used to treat chronic immune (idiopathic) thrombocytopenia (ITP) in patients who have not responded adequately to other treatments like corticosteroids, immunoglobulins, or splenectomy, by helping the body produce more platelets.

What are the common side effects of eltrombopag?

Commonly reported side effects include nausea, diarrhea, vomiting, headache, and fatigue, along with upper respiratory tract infection and rash in some patients.

At what age is eltrombopag approved for chronic ITP?

For chronic immune (idiopathic) thrombocytopenia, eltrombopag is approved for patients aged 1 year and older who have had an insufficient response to prior therapies.

Does eltrombopag require any special monitoring during treatment?

Yes, regular monitoring of liver function is important due to the risk of hepatotoxicity, and physicians also watch for signs of thrombotic events and other serious reactions throughout therapy.

Which eltrombopag brands are available for export to Saudi Arabia?

We supply four Bangladeshi-manufactured eltrombopag brands for export to Saudi Arabia: Trombola, Treptora, Elopag, and Elbonix.

How can pharmacies or distributors in Saudi Arabia inquire about pricing and availability?

Pricing and stock details are not published publicly and are provided upon direct inquiry to ensure accuracy for each order, so interested pharmacies, hospitals, and distributors are encouraged to contact our team directly.

  1. 1. www.elbonix.com.bd
  2. 2. global.beaconpharma.com.bd
  3. 3. dailymed.nlm.nih.gov
  4. 4. www.drugs.com
  5. 5. www.drugs.com
  6. 6. www.drugs.com
  7. 7. www.drugs.com

Access This Medicine Through Saif Pharma

We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.

We do not publish prices online. All pricing is provided directly by our specialist supply team on request.

error: Content is protected !!